TY - JOUR
T1 - Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma
T2 - a systematic review and meta-analysis
AU - Japan Duodenal Cancer Guideline Committee
AU - Burasakarn, Pipit
AU - Higuchi, Ryota
AU - Nunobe, Souya
AU - Kanaji, Shingo
AU - Eguchi, Hidetoshi
AU - Okada, Ken ichi
AU - Fujii, Tsutomu
AU - Nagakawa, Yuichi
AU - Kanetaka, Kengo
AU - Yamashita, Hiroharu
AU - Yamada, Suguru
AU - Kuroda, Shinji
AU - Aoyama, Toru
AU - Akahori, Takahiro
AU - Nakagawa, Kenji
AU - Yamamoto, Masakazu
AU - Yamaue, Hiroki
AU - Sho, Masayuki
AU - Kodera, Yasuhiro
AU - Nunobe, S. N.Souya
AU - Kanaji, S. K.Shingo
AU - Eguchi, H. E.Hidetoshi
AU - Okada, K. O.Ken ichi
AU - Fujii, T. F.Tsutomu
AU - Nagakawa, Y. N.Yuichi
AU - Kanetaka, K. K.Kengo
AU - Yamashita, H. Y.Hiroharu
AU - Yamada, S. Y.Suguru
AU - Kuroda, S. K.Shinji
AU - Aoyama, T. A.Toru
AU - Akahori, T. A.Takahiro
AU - Nakagawa, K. N.Kenji
AU - Higuchi, R. H.Ryota
AU - Yamaue, H. Y.Hiroki
AU - Sho, M. S.Masayuki
AU - Kodera, Y. K.Yasuhiro
N1 - Funding Information:
This work was supported by the Health and Labor Sciences Research Grant (Grant number H29-GANTAISAKU-IPPAN-013) and JSPS KAKENHI (Grant number 18K08632). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Funding Information:
We would like to thank the Japan Duodenal Cancer Guideline Committee and many doctors related to this research opportunity. Japan Duodenal Cancer Guideline Committee: S. N. Souya Nunobe, S. K. Shingo Kanaji, H. E. Hidetoshi Eguchi, K. O. Ken-ichi Okada, T. F. Tsutomu Fujii, Y. N. Yuichi Nagakawa, K. K. Kengo Kanetaka, H. Y. Hiroharu Yamashita, S. Y. Suguru Yamada, S. K.Shinji Kuroda, T. A. Toru Aoyama, T. A. Takahiro Akahori, K. N. Kenji Nakagawa, R. H. Ryota Higuchi, H. Y. Hiroki Yamaue, M. S. Masayuki Sho, Y. K. Yasuhiro Kodera.
Publisher Copyright:
© 2021, Japan Society of Clinical Oncology.
PY - 2021/3
Y1 - 2021/3
N2 - It is well known that surgery is the mainstay treatment for duodenal adenocarcinoma. However, the optimal extent of surgery is still under debate. We aimed to systematically review and perform a meta-analysis of limited resection (LR) and pancreatoduodenectomy for patients with duodenal adenocarcinoma. A systematic electronic database search of the literature was performed using PubMed and the Cochrane Library. All studies comparing LR and pancreatoduodenectomy for patients with duodenal adenocarcinoma were selected. Long-term overall survival was considered as the primary outcome, and perioperative morbidity and mortality as the secondary outcomes. Fifteen studies with a total of 3166 patients were analyzed; 995 and 1498 patients were treated with limited resection and pancreatoduodenectomy, respectively. Eight and 7 studies scored a low and intermediate risk of publication bias, respectively. The LR group had a more favorable result than the pancreatoduodenectomy group in overall morbidity (odd ratio [OR]: 0.33, 95% confidence interval [CI] 0.17–0.65) and postoperative pancreatic fistula (OR: 0.13, 95% CI 0.04–0.43). Mortality (OR: 0.96, 95% CI 0.70–1.33) and overall survival (OR: 0.61, 95% CI 0.33–1.13) were not significantly different between the two groups, although comparison of the two groups stratified by prognostic factors, such as T categories, was not possible due to a lack of detailed data. LR showed long-term outcomes equivalent to those of pancreatoduodenectomy, while the perioperative morbidity rates were lower. LR could be an option for selected duodenal adenocarcinoma patients with appropriate location or depth of invasion, although further studies are required.
AB - It is well known that surgery is the mainstay treatment for duodenal adenocarcinoma. However, the optimal extent of surgery is still under debate. We aimed to systematically review and perform a meta-analysis of limited resection (LR) and pancreatoduodenectomy for patients with duodenal adenocarcinoma. A systematic electronic database search of the literature was performed using PubMed and the Cochrane Library. All studies comparing LR and pancreatoduodenectomy for patients with duodenal adenocarcinoma were selected. Long-term overall survival was considered as the primary outcome, and perioperative morbidity and mortality as the secondary outcomes. Fifteen studies with a total of 3166 patients were analyzed; 995 and 1498 patients were treated with limited resection and pancreatoduodenectomy, respectively. Eight and 7 studies scored a low and intermediate risk of publication bias, respectively. The LR group had a more favorable result than the pancreatoduodenectomy group in overall morbidity (odd ratio [OR]: 0.33, 95% confidence interval [CI] 0.17–0.65) and postoperative pancreatic fistula (OR: 0.13, 95% CI 0.04–0.43). Mortality (OR: 0.96, 95% CI 0.70–1.33) and overall survival (OR: 0.61, 95% CI 0.33–1.13) were not significantly different between the two groups, although comparison of the two groups stratified by prognostic factors, such as T categories, was not possible due to a lack of detailed data. LR showed long-term outcomes equivalent to those of pancreatoduodenectomy, while the perioperative morbidity rates were lower. LR could be an option for selected duodenal adenocarcinoma patients with appropriate location or depth of invasion, although further studies are required.
KW - Duodenal adenocarcinoma
KW - Duodenal cancer
KW - Limited resection
KW - Pancreatoduodenectomy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85098488742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098488742&partnerID=8YFLogxK
U2 - 10.1007/s10147-020-01840-5
DO - 10.1007/s10147-020-01840-5
M3 - Review article
C2 - 33386555
AN - SCOPUS:85098488742
SN - 1341-9625
VL - 26
SP - 450
EP - 460
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 3
ER -